Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcemic hyperparathyroidism

Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose To evaluate the positivity...

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 96; no. 6; pp. 831 - 836
Main Authors Musumeci, Martina, Pereira, Lucía Valeria, San Miguel, Lucas, Cianciarelli, Constanza, Vazquez, Eliana Cecilia, Mollerach, Ana María, Arma, Irene Josefa, Hume, Isabel, Galich, Ana María, Collaud, Carlos
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.06.2022
Subjects
Online AccessGet full text
ISSN0300-0664
1365-2265
1365-2265
DOI10.1111/cen.14667

Cover

Abstract Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose To evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). Materials and Methods We retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). Results The detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Conclusion Localization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it.
AbstractList ContextNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.PurposeTo evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).Materials and MethodsWe retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).ResultsThe detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.ConclusionLocalization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it.
Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.CONTEXTNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.To evaluate the positivity rate of 99m Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).PURPOSETo evaluate the positivity rate of 99m Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).We retrospectively studied 125 patients with 99m Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).MATERIALS AND METHODSWe retrospectively studied 125 patients with 99m Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).The detection rate of 99m Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.RESULTSThe detection rate of 99m Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.Localization rate of parathyroid hyperfunctioning tissue with 99m Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18 F-Choline PET/CT when the clinical context justifies it.CONCLUSIONLocalization rate of parathyroid hyperfunctioning tissue with 99m Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18 F-Choline PET/CT when the clinical context justifies it.
Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. To evaluate the positivity rate of Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). We retrospectively studied 125 patients with Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). The detection rate of Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Localization rate of parathyroid hyperfunctioning tissue with Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as F-Choline PET/CT when the clinical context justifies it.
Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose To evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). Materials and Methods We retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). Results The detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Conclusion Localization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it.
Author Musumeci, Martina
San Miguel, Lucas
Pereira, Lucía Valeria
Vazquez, Eliana Cecilia
Galich, Ana María
Hume, Isabel
Collaud, Carlos
Cianciarelli, Constanza
Arma, Irene Josefa
Mollerach, Ana María
Author_xml – sequence: 1
  givenname: Martina
  orcidid: 0000-0002-9840-7225
  surname: Musumeci
  fullname: Musumeci, Martina
  email: martina.musumeci@hospitalitaliano.org.ar
  organization: Hospital Italiano de Buenos Aires
– sequence: 2
  givenname: Lucía Valeria
  surname: Pereira
  fullname: Pereira, Lucía Valeria
  organization: Hospital Italiano de Buenos Aires
– sequence: 3
  givenname: Lucas
  surname: San Miguel
  fullname: San Miguel, Lucas
  organization: Hospital Italiano de Buenos Aires
– sequence: 4
  givenname: Constanza
  surname: Cianciarelli
  fullname: Cianciarelli, Constanza
  organization: Hospital Italiano de Buenos Aires
– sequence: 5
  givenname: Eliana Cecilia
  surname: Vazquez
  fullname: Vazquez, Eliana Cecilia
  organization: Hospital Italiano de Buenos Aires
– sequence: 6
  givenname: Ana María
  surname: Mollerach
  fullname: Mollerach, Ana María
  organization: Hospital Italiano de Buenos Aires
– sequence: 7
  givenname: Irene Josefa
  surname: Arma
  fullname: Arma, Irene Josefa
  organization: Hospital Italiano de Buenos Aires
– sequence: 8
  givenname: Isabel
  surname: Hume
  fullname: Hume, Isabel
  organization: Hospital Italiano de Buenos Aires
– sequence: 9
  givenname: Ana María
  surname: Galich
  fullname: Galich, Ana María
  organization: Hospital Italiano de Buenos Aires
– sequence: 10
  givenname: Carlos
  surname: Collaud
  fullname: Collaud, Carlos
  organization: Hospital Italiano de Buenos Aires
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34951035$$D View this record in MEDLINE/PubMed
BookMark eNp1kVtLwzAYhoMobh4u_ANS8EYvuiXNqfVOyjyAJ9i8DkmasUjbzKRF5q83uunF0NyEwPM-fHm_A7DbutYAcILgCMUz1qYdIcIY3wFDhBlNs4zRXTCEGMIUMkYG4CCEVwghzSHfBwNMCoogpkPw8eh847SstWmsTpbeNtKvksVqafxSetktVt7ZyobmMimKZqaTqQmdfLDKJtPnSTkbl7PEm9DXXUi0a2LGJO-2W6wVv-I_hEdgby7rYI439yF4uZ7Mytv0_unmrry6TzWmmKc400byghdM0UorjopMKUwUqaiJL6lJ_HI-hxCTqqI5zbhiLMdUKa45YQgfgvO1d-ndWx-nF40N2tS1bI3rg8gYIhlGsZOInm2hr673bZwuUtGNipyRSJ1uqF41phKb0sRPqxEYrwHtXQjezIW2neysazsvbS0QFF97E3Fv4ntvMXGxlfiR_sVu7O-2Nqv_QVFOHteJT5Tep3Y
CitedBy_id crossref_primary_10_20945_2359_3997000000556
crossref_primary_10_1210_jendso_bvad013
crossref_primary_10_1210_clinem_dgae659
crossref_primary_10_3390_medicina60010015
crossref_primary_10_1007_s12020_022_03280_9
crossref_primary_10_3390_jcm12030812
Cites_doi 10.1157/13109149
10.1001/jamasurg.2016.2310
10.1007/s40618-018-0931-z
10.1089/thy.2010.0035
10.1210/jc.2014-1414
10.1159/000491036
10.1245/s10434-011-1870-5
10.1210/jc.2002-021404
10.1210/jc.2008-1763
10.1016/j.beem.2018.09.009
10.1016/j.amjsurg.2019.10.032
10.1001/jamaoto.2019.0574
10.1007/s00198-016-3716-2
10.1038/nrendo.2017.104
10.1002/lary.26201
10.1007/s00268-012-1438-y
10.1007/s00423-019-01782-1
10.1210/jc.2007-1215
10.1007/s00268-018-4512-2
10.4158/EP15704.OR
10.1210/jc.2014-1417
ContentType Journal Article
Copyright 2021 John Wiley & Sons Ltd.
2022 John Wiley & Sons Ltd.
Copyright_xml – notice: 2021 John Wiley & Sons Ltd.
– notice: 2022 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
K9.
NAPCQ
7X8
DOI 10.1111/cen.14667
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2265
EndPage 836
ExternalDocumentID 34951035
10_1111_cen_14667
CEN14667
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
08P
0R~
10A
1OB
1OC
29B
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
REN
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c3537-32cea79796b5dcb7192bb34b4d5eb71ac41368f0034dd58527b66835bb7c74613
IEDL.DBID DR2
ISSN 0300-0664
1365-2265
IngestDate Tue Aug 05 11:35:26 EDT 2025
Mon Oct 06 18:15:20 EDT 2025
Wed Feb 19 02:26:23 EST 2025
Thu Apr 24 23:06:02 EDT 2025
Wed Oct 01 02:17:19 EDT 2025
Wed Jan 22 16:24:59 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords hypercalcemic hyperparathyroidism
normocalcemic hyperparathyroidism
SPECT/CT
parathyroid scintigraphy
Language English
License 2021 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3537-32cea79796b5dcb7192bb34b4d5eb71ac41368f0034dd58527b66835bb7c74613
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9840-7225
PMID 34951035
PQID 2658519864
PQPubID 36523
PageCount 6
ParticipantIDs proquest_miscellaneous_2614231349
proquest_journals_2658519864
pubmed_primary_34951035
crossref_citationtrail_10_1111_cen_14667
crossref_primary_10_1111_cen_14667
wiley_primary_10_1111_cen_14667_CEN14667
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2022
2022-06-00
2022-Jun
20220601
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: June 2022
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Clinical endocrinology (Oxford)
PublicationTitleAlternate Clin Endocrinol (Oxf)
PublicationYear 2022
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2019; 8
2018; 6
2017; 6
2010; 10
2017; 1
2012; 2
2019; 4
2018; 2
2019; 51
2016; 3
2020; 1
2009; 94
2016; 10
2008; 9
2020; 105
2012; 6
2018; 11
2018; 42
2003; 10
2014; 10
2007; 26
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
Pierreux J (e_1_2_8_13_1) 2018; 11
e_1_2_8_24_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_7_1
Schini M (e_1_2_8_4_1) 2020; 105
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_10_1
e_1_2_8_21_1
e_1_2_8_11_1
e_1_2_8_22_1
e_1_2_8_12_1
e_1_2_8_23_1
References_xml – volume: 6
  start-page: 761
  year: 2012
  end-page: 766
  article-title: Surgical management of normocalcemic primary hyperparathyroidism
  publication-title: World J Surg
– volume: 10
  start-page: 3570
  year: 2014
  end-page: 3579
  article-title: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop
  publication-title: J Clin Endocrinol Metab
– volume: 1
  start-page: 150
  year: 2020
  end-page: 153
  article-title: Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?
  publication-title: Am J Surg
– volume: 10
  start-page: 4641
  year: 2003
  end-page: 4648
  article-title: Normocalcemic primary hyperparathyroidism: evidence for a generalized target‐tissue resistance to parathyroid hormone
  publication-title: J Clin Endocrinol Metab
– volume: 26
  start-page: 310
  year: 2007
  end-page: 328
  article-title: Gammagrafía de paratiroides y cirugía radiodirigida en el hiperparatiroidismo primario
  publication-title: Rev Esp Med Nucl Imagen Mol
– volume: 10
  start-page: 1121
  year: 2010
  end-page: 1127
  article-title: Clinical appraisal of 99m technetium‐sestamibi SPECT/CT compared to conventional SPECT in patients with primary hyperparathyroidism and concomitant nodular goiter
  publication-title: Thyroid
– volume: 2
  start-page: 115
  year: 2018
  end-page: 125
  article-title: Primary hyperparathyroidism
  publication-title: Nat Rev Endocrinol
– volume: 51
  start-page: 23
  year: 2019
  end-page: 39
  article-title: Normocalcemic hyperparathyroidism
  publication-title: Front Horm Res
– volume: 2
  start-page: 577
  year: 2012
  end-page: 583
  article-title: A meta‐analysis of preoperative localization techniques for patients with primary hyperparathyroidism
  publication-title: Ann Surg Oncol
– volume: 3
  start-page: 294
  year: 2016
  end-page: 301
  article-title: Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?
  publication-title: Endocr Pract
– volume: 1
  start-page: 1
  year: 2017
  end-page: 19
  article-title: Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus
  publication-title: Osteoporos Int
– volume: 10
  start-page: 959
  year: 2016
  end-page: 968
  article-title: The American Association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism
  publication-title: JAMA Surg
– volume: 4
  start-page: 419
  year: 2019
  end-page: 426
  article-title: PETC/CT with 18F‐Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism
  publication-title: J Endocrinol Invest
– volume: 94
  start-page: 335
  year: 2009
  end-page: 339
  article-title: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop
  publication-title: J Clin Endocrinol Metab
– volume: 42
  start-page: 992
  year: 2018
  end-page: 997
  article-title: Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ?
  publication-title: World J Surg
– volume: 8
  start-page: 743
  year: 2019
  end-page: 750
  article-title: Usefulness of 18F‐fluorocholine positron emission tomography‐computed tomography in locating lesions in Hyperparathyroidism: a systematic review
  publication-title: JAMA Otolaryngol Head Neck Surg
– volume: 11
  start-page: 797
  year: 2018
  end-page: 802
  article-title: Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population
  publication-title: Horm Metab Res
– volume: 9
  start-page: 3462
  year: 2008
  end-page: 3470
  article-title: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years
  publication-title: J Clin Endocrinol Metab
– volume: 6
  start-page: 837
  year: 2018
  end-page: 845
  article-title: Management of normocalcemic primary hyperparathyroidism
  publication-title: Best Prac Res Clin Endocrinol Metab
– volume: 4
  start-page: 431
  year: 2019
  end-page: 438
  article-title: Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate
  publication-title: Langenbecks Arch Surg
– volume: 6
  start-page: 1476
  year: 2017
  end-page: 1482
  article-title: Four‐dimensional computed tomography scan utility in parathyroidectomy for primary hyperparathyroidism with low baseline intact parathyroid hormone
  publication-title: Laryngoscope
– volume: 105
  year: 2020
  article-title: Normocalcemic hyperparathyroidism: study of its prevalence and natural history
  publication-title: J Clin Endocrinol Metab
– volume: 10
  start-page: 3607
  year: 2014
  end-page: 3618
  article-title: Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism
  publication-title: J Clin Endocrinol Metab
– ident: e_1_2_8_15_1
  doi: 10.1157/13109149
– ident: e_1_2_8_18_1
  doi: 10.1001/jamasurg.2016.2310
– ident: e_1_2_8_21_1
  doi: 10.1007/s40618-018-0931-z
– volume: 105
  year: 2020
  ident: e_1_2_8_4_1
  article-title: Normocalcemic hyperparathyroidism: study of its prevalence and natural history
  publication-title: J Clin Endocrinol Metab
– ident: e_1_2_8_16_1
  doi: 10.1089/thy.2010.0035
– ident: e_1_2_8_3_1
  doi: 10.1210/jc.2014-1414
– ident: e_1_2_8_5_1
  doi: 10.1159/000491036
– volume: 11
  start-page: 797
  year: 2018
  ident: e_1_2_8_13_1
  article-title: Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population
  publication-title: Horm Metab Res
– ident: e_1_2_8_7_1
  doi: 10.1245/s10434-011-1870-5
– ident: e_1_2_8_12_1
  doi: 10.1210/jc.2002-021404
– ident: e_1_2_8_2_1
  doi: 10.1210/jc.2008-1763
– ident: e_1_2_8_8_1
  doi: 10.1016/j.beem.2018.09.009
– ident: e_1_2_8_10_1
  doi: 10.1016/j.amjsurg.2019.10.032
– ident: e_1_2_8_19_1
  doi: 10.1001/jamaoto.2019.0574
– ident: e_1_2_8_6_1
  doi: 10.1007/s00198-016-3716-2
– ident: e_1_2_8_22_1
  doi: 10.1038/nrendo.2017.104
– ident: e_1_2_8_20_1
  doi: 10.1002/lary.26201
– ident: e_1_2_8_14_1
  doi: 10.1007/s00268-012-1438-y
– ident: e_1_2_8_17_1
  doi: 10.1007/s00423-019-01782-1
– ident: e_1_2_8_23_1
  doi: 10.1210/jc.2007-1215
– ident: e_1_2_8_11_1
  doi: 10.1007/s00268-018-4512-2
– ident: e_1_2_8_9_1
  doi: 10.4158/EP15704.OR
– ident: e_1_2_8_24_1
  doi: 10.1210/jc.2014-1417
SSID ssj0005807
Score 2.408819
Snippet Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the...
Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the...
ContextNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 831
SubjectTerms Calcium (blood)
Computed tomography
Humans
Hypercalcemia
hypercalcemic hyperparathyroidism
Hyperparathyroidism
Hyperparathyroidism, Primary - diagnostic imaging
Localization
Medical imaging
normocalcemic hyperparathyroidism
Parathyroid
Parathyroid Glands - diagnostic imaging
Parathyroid hormone
parathyroid scintigraphy
Patients
Positron Emission Tomography Computed Tomography - methods
Retrospective Studies
Single photon emission computed tomography
SPECT/CT
Technetium Tc 99m Sestamibi
Tomography, Emission-Computed, Single-Photon
Ultrasonic imaging
Title Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcemic hyperparathyroidism
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.14667
https://www.ncbi.nlm.nih.gov/pubmed/34951035
https://www.proquest.com/docview/2658519864
https://www.proquest.com/docview/2614231349
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0300-0664
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1365-2265
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005807
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7Eg3jx_VhfRPHgpeq2adLqSZZdRNhFdAUPQmnSLC5qV_Zx0F_vTJrWN4i3PqZJm2Qy3yQzXwH2eU_GfqS5h_1rPG5S7hGLt4fWBW_IIIuMjfLtiPMbfnEb3k7BaZkLU_BDVAtupBl2viYFT9Xog5Jrk5OaC8okrwfCulNX79RRoUuVDihzWgjuWIUoiqd68rMt-gYwP-NVa3Ba83BXvmoRZ_JwOBmrQ_36hcXxn9-yAHMOiLKzYuQswpTJl2Cm7bbal-G1g2iWDJ2m8Hn2XLBSsHv0W4eWL_z-ZTjoZ_3R0wmL46euZtf4VWm7r_rs-rLZ6B41ugx9-cnjeMRcpDujVd-iiKrgHwpcgZtWs9s499yPGjwdhAFOUr42qYxlLFSYaSURNSoVcMWz0OBZqtFSiqhHXDhZhv6JL5UQCP2UklpyBBSrMJ0PcrMOjAdCIaaLZFTvcf9YqhgRLU-1MkpnMQ9qcFB2WaIdizn9TOMxKb0ZbMvEtmUN9ipR10g_CW2V_Z447R0lvqDNUiKur8FudRv1jjZT0twMJiRTRyRK5I41WCvGS1ULXiSiwhBf1vb679UnjWbHHmz8XXQTZn3KwbBLQVswPR5OzDYio7HasSrwBnfwCMI
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT9wwFH4CKhUudGHptJSaigOXsCSOnSAuaDRoWGaESpC4oCh2PGIEZKpZDvDr-57jhKUgIW5J7Hh_ft-znz8DrPOejP1Icw_713jcZNwjFm8PtQsGyCCPjPXy7Yr2OT-6CC-mYK86C1PyQ9QLbiQZdr4mAacF6UdSrk1Bci7kNHzgAu0UgkR_HsijQndYOqCz00JwxytEfjz1r0-10X8Q8ylitSrn4BNcVoUtPU2uNydjtanvn_E4vrc2n2HeYVG2Xw6eLzBliq_wseN22xfgvouAlnSdJg969rckpmBXaLoOLWX41d1w0M_7o9tdFse3iWZnWK2s01d9dnbaaiZbzYShOT-5GY-Yc3ZntPBbJlEn_EKCi3B-0Eqabc_d1eDpIAxwnvK1yWQsY6HCXCuJwFGpgCuehwbfMo3KUkQ9osPJczRRfKmEQPSnlNSSI6ZYgpliUJhvwHggFMK6SEY7Pe5vSxUjqOWZVkbpPOZBAzaqPku1IzKn-zRu0sqgwbZMbVs24Hcd1TXSS5FWqo5PnQCPUl_Qfilx1zdgrQ5G0aP9lKwwgwnF2UEwSvyODVguB0ydC34krsIQC2u7_fXs02arax--vz3qL5htJ52T9OSwe_wD5nw6kmFXhlZgZjycmJ8IlMZq1crDPwenDOM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlRAXoAXK8mhdxKGXQDdx7ARxQcuuKJQVKovEBUWx4xUr2OxqHwf49cw4TiiUSqi3JJ74PZ7P9vgzwC7vytiPNPewfY3HTco9YvH20LpggAyyyFgv37Y4ueKn1-H1DByWZ2EKfohqwY00w47XpOBmmHX_0HJtctJzIWfhAw_jiBz6jn8_k0eF7rB0QGenheCOV4j8eKpfX1qjvyDmS8RqTU5rCW7KzBaeJnd704na04-veBz_tzTLsOiwKDsqOs9HmDH5J5g_d7vtK_DYRkBLtk6TBz0bFsQU7BanriNLGX77MBr0st64f8DiuN_R7BKLlZ73VI9dXjQbnf1Gh-F0fno_GTPn7M5o4beIoor4jQhX4arV7DROPHdXg6eDMMBxytcmlbGMhQozrSQCR6UCrngWGnxLNRpLEXWJDifLcIriSyUEoj-lpJYcMcUazOWD3KwD44FQCOsiGdW73P8hVYyglqdaGaWzmAc1-F62WaIdkTndp3GflBMarMvE1mUNdipRV0lvCW2VDZ84BR4nvqD9UuKur8G3KhhVj_ZT0twMpiRTRzBK_I41-Fx0mCoV_EhchSFm1jb7v5NPGs22fdh4v-hXmL84biW_frbPNmHBpxMZdmFoC-Ymo6nZRpw0UV-sOjwBngAMZw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Normocalcemic+primary+hyperparathyroidism%3A+99mTc+SestaMibi+SPECT%2FCT+results+compare+with+hypercalcemic+hyperparathyroidism&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Musumeci%2C+Martina&rft.au=Pereira%2C+Luc%C3%ADa+Valeria&rft.au=San+Miguel%2C+Lucas&rft.au=Cianciarelli%2C+Constanza&rft.date=2022-06-01&rft.issn=1365-2265&rft.eissn=1365-2265&rft.volume=96&rft.issue=6&rft.spage=831&rft_id=info:doi/10.1111%2Fcen.14667&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon